Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132


The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies.

Park KH, Shin JH, Lee SY, Kim SH, Jang MO, Kang SJ, Jung SI, Chung EK, Ko KS, Jang HC.

PLoS One. 2013 Jun 3;8(6):e65026. doi: 10.1371/journal.pone.0065026. Print 2014.


Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance.

Fitzpatrick MA, Ozer E, Bolon MK, Hauser AR.

J Infect. 2015 Feb;70(2):144-52. doi: 10.1016/j.jinf.2014.09.004. Epub 2014 Sep 19.


Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.

Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Paniara O, Giamarellou H, Roussos C.

Infection. 2010 Jun;38(3):173-80. doi: 10.1007/s15010-010-0008-1. Epub 2010 Mar 12.


Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.

Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti-Yin, Chen TL, Fung CP.

J Microbiol Immunol Infect. 2012 Oct;45(5):356-62. doi: 10.1016/j.jmii.2011.12.009. Epub 2012 May 9.


Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.

Chiang MC, Kuo SC, Chen SJ, Yang SP, Lee YT, Chen TL, Fung CP.

Infection. 2012 Feb;40(1):19-26. doi: 10.1007/s15010-011-0187-4. Epub 2011 Sep 2.


Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes.

Lee YC, Huang YT, Tan CK, Kuo YW, Liao CH, Lee PI, Hsueh PR.

J Antimicrob Chemother. 2011 Aug;66(8):1839-46. doi: 10.1093/jac/dkr200. Epub 2011 Jun 8.


Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.

Lee HY, Chen CL, Wu SR, Huang CW, Chiu CH.

Crit Care Med. 2014 May;42(5):1081-8. doi: 10.1097/CCM.0000000000000125.


Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.

Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW.

J Korean Med Sci. 2012 May;27(5):471-5. doi: 10.3346/jkms.2012.27.5.471. Epub 2012 Apr 25.


Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.

Anunnatsiri S, Tonsawan P.

Southeast Asian J Trop Med Public Health. 2011 May;42(3):693-703.


Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.

Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC.

Crit Care Med. 2015 Jun;43(6):1194-204. doi: 10.1097/CCM.0000000000000933.


Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.

Vandepitte WP, Berge J, Andersson R.

J Med Assoc Thai. 2014 Nov;97 Suppl 11:S129-39.


Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH.

Antimicrob Agents Chemother. 2011 Oct;55(10):4844-9. doi: 10.1128/AAC.01728-10. Epub 2011 Aug 8.


Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea.

Park YK, Jung SI, Park KH, Kim SH, Ko KS.

Int J Antimicrob Agents. 2012 Jan;39(1):81-5. doi: 10.1016/j.ijantimicag.2011.08.006. Epub 2011 Oct 12.


Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections.

Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ.

J Med Microbiol. 2011 May;60(Pt 5):605-11. doi: 10.1099/jmm.0.029439-0. Epub 2011 Jan 13.


Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii.

Chusri S, Chongsuvivatwong V, Rivera JI, Silpapojakul K, Singkhamanan K, McNeil E, Doi Y.

Antimicrob Agents Chemother. 2014 Jul;58(7):4172-9. doi: 10.1128/AAC.02992-14. Epub 2014 May 12.


Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.

Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, He YQ, Chen JH.

Am J Infect Control. 2013 Jul;41(7):e59-63. doi: 10.1016/j.ajic.2013.01.006. Epub 2013 Mar 21.


Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis.

Yang YS, Lee YT, Tsai WC, Kuo SC, Sun JR, Yang CH, Chen TL, Lin JC, Fung CP, Chang FY.

BMC Infect Dis. 2013 Jul 10;13:311. doi: 10.1186/1471-2334-13-311.


Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years.

Park YK, Jung SI, Park KH, Kim DH, Choi JY, Kim SH, Ko KS.

J Med Microbiol. 2012 Jan;61(Pt 1):71-9. doi: 10.1099/jmm.0.033852-0. Epub 2011 Aug 18.


Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit.

Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, Park SC, Chung KS, Park BH, Kim YS, Kim SK, Chang J, Park MS.

J Korean Med Sci. 2012 Aug;27(8):939-47. doi: 10.3346/jkms.2012.27.8.939. Epub 2012 Jul 25.


Recurrent bacteremia caused by the Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

Lai CC, Hsu HL, Tan CK, Tsai HY, Cheng A, Liu CY, Huang YT, Liao CH, Sheng WH, Hsueh PR.

J Clin Microbiol. 2012 Sep;50(9):2982-6. doi: 10.1128/JCM.01194-12. Epub 2012 Jul 3.

Items per page

Supplemental Content

Write to the Help Desk